摘要
目的:探讨精子蛋白17在上皮性卵巢癌组织中的表达及其与卵巢癌组织学分型,肿瘤分化程度及临床分期预后的关系。方法:对48例上皮性卵巢癌手术切除的石蜡包埋组织标本用自制的Sp17单克隆抗体进行免疫组化染色,研究Sp17在卵巢癌组织中的表达,并结合临床资料,探讨Sp17的表达与卵巢癌组织学分型、肿瘤分化程度(分级)及临床分期、预后的关系。结果:Sp17在上皮性卵巢癌的阳性表达率达43.8%(21/48),Sp17的表达与上皮性卵巢癌的组织学类型、肿瘤分化程度及临床分期无相关性,Sp17阳性患者生存时间似较阴性者为长,但无统计学意义。结论:Sp17在上皮性卵巢癌中有较高的表达率,值得进一步研究。
Objective： To investigate the expression of sperm 17（Sp17） in epithelial ovarian cancer and the relationship between Sp17 expression and epithelial histologic subtype,tumor differentiation（grade）,clinical staging.We also want to know whether patients with Sp17 positive live longer than those with Sp17 negative.Mehtod： The expression of Sp17 was assessed by means of a standardized immunohistochemical procedure in formalin-fixed and paraffin embedded surgical specimen of 48 epithelial ovarian cancer.We then review the relationship between the expression of SP17 and histologic subtype、degree of differentiation、clinical staging and diagnosis of epithelial ovarian cancer.Result： 21 specimen of epithelial ovarian cancer was found immunopositive for Sp17.The expression of Sp17 did not correlate with histologic subtype 、degree of differentiation、clinical staging of epithelial ovarian cancer.The overall survival time of patients with SP17 positive seems to be longer than those with SP17negative,but no statistic significance was found between these two groups.Conclusion： The high frequency of SP17 expression in epithelial ovarian cancer suggests that it can be a potential immunotherapeutic target in ovarian cancer.
出处
《河北医学》
CAS
2007年第7期785-788,共4页
Hebei Medicine
